The combination of transforming growth factor (TGF)-beta-blockade and immunotherapy has also been explored through the use of Bintrafuspalpfa (M7824), a bifunctional antibody that targets PD-L1 while linked to an extracellular domain of TGF-beta receptors that trap TGF-beta within the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.